Galenika launches a therapy for the treatment of obesity
03/03/2026 • Customer news
In response to the dramatic rise in obesity and related chronic diseases, Galenika has made a strategic move through a partnership with EMS – its sister company from Brazil – introducing a new-generation therapy and reaffirming its role as a regional leader in modern pharmaceuticals.
At a time when obesity is reaching the scale of a global epidemic, Galenika is launching a new era in the fight against obesity by introducing a modern GLP-1 therapy, opening a new chapter in the prevention and treatment of 21st-century diseases.
With the increase in diabetes, cardiovascular, and metabolic diseases, the need for advanced therapeutic solutions has never been greater. By strategically entering the GLP-1 therapy segment, the pharmaceutical company Galenika is positioning itself at the center of one of the most dynamic and promising fields of modern medicine, responding to growing healthcare and market needs. With this therapeutic solution in the field of metabolism, the company is strengthening its portfolio and confirming its long-term strategy of innovation and development in segments with the highest medical and economic potential.
You can read the full article here.
